Shigella Antibiotic Treatment
For uncomplicated Shigella infection, ciprofloxacin (15 mg/kg/day) is the first-line antibiotic for children, with azithromycin or cefixime as alternatives when ciprofloxacin resistance is known or suspected. 1
First-Line Treatment
The most recent WHO-aligned guidelines (2024) recommend ciprofloxacin as first-line therapy for shigellosis in children, despite concerns about arthropathy, because shigellosis is one of the few indications where this antibiotic is highly effective and appropriately used in this age group 1. The recommended dose is 15 mg/kg once daily.
Key Consideration: Resistance Patterns Matter
Avoid fluoroquinolones if the ciprofloxacin MIC is ≥0.12 μg/mL, even if the laboratory reports susceptibility 2. This is critical because resistance to ciprofloxacin has been increasing, particularly in Asia-Africa regions where resistance rates reached 5.0% (compared to 0.3% in Europe-America) 1.
Second-Line Alternatives
When ciprofloxacin resistance is documented or suspected:
Azithromycin: Highly effective against multidrug-resistant Shigella strains. Clinical trials show 82% clinical success rate, comparable to ciprofloxacin (89%) 3. Particularly valuable in regions with high fluoroquinolone resistance 1.
Cefixime (oral third-generation cephalosporin): Effective alternative, though resistance is emerging. Resistance rates to ceftriaxone were 2.5% in Asia-Africa but increased to 14.2% after 2007 1.
Ceftriaxone (parenteral): Reserved for severe cases or treatment failures. Resistance varies significantly by region (0.4% in Europe-America vs. 2.5% in Asia-Africa) 1.
Treatment Duration and Monitoring
Assess clinical response within 48 hours 4. If no improvement:
- Switch to an alternative antibiotic from the recommended list
- Reassess after another 48 hours
- If still no improvement, refer for stool microscopy to rule out amebiasis or confirm resistant Shigellosis 4
Outdated Regimens to Avoid
The older guidelines from 1992 recommended ampicillin and TMP-SMX as first-line agents 4. These are no longer appropriate for empiric therapy due to widespread resistance. Studies show approximately 37% of Shigella isolates demonstrate resistance to both ampicillin and TMP-SMX 5. High resistance rates persist globally 1.
Critical Pitfalls
Do not rely on dysentery (bloody diarrhea) alone to identify Shigella: Dysentery identifies only 1.9-85.9% of confirmed Shigella infections, with sensitivity decreasing over time 6. Importantly, Shigella infection without dysentery is still associated with significant mortality (OR 2.8), while dysentery itself is not associated with mortality (OR 1.3) 6.
Do not use antibiotics for prophylaxis: WHO explicitly does not recommend mass prophylaxis or prophylaxis of family members 4.
Emerging Resistance Concerns
Recent surveillance data (2026) shows alarming resistance patterns across multiple sites:
- Ciprofloxacin resistance: 37.2% (range 14.0-74.0%)
- Azithromycin resistance: 22.1% (range 1.2-34.2%)
- Ceftriaxone resistance: 16.2% (range 0.0-64.4%) 7
Always obtain local susceptibility data when available to guide empiric therapy 4. The choice of first-line drug should be based on knowledge of local susceptibility patterns, as resistance varies dramatically by geographic region.
Special Populations
For adults with uncomplicated Shigella, the same principles apply, though dosing differs:
- Ciprofloxacin: 500 mg twice daily for 3-5 days
- Azithromycin: 500 mg day 1, then 250 mg daily for 4 days 3